Key Details
The amendment to Rule 43A of the Drugs Rules, 1945 adds Navi Mumbai Airport to the list of authorised ports for importing drugs under the Drugs and Cosmetics Act, 1940, increasing the total number of notified entry points to 42.
Area | Key Detail | Why It Matters |
|---|---|---|
Regulatory change | Navi Mumbai Airport has been notified under Rule 43A of the Drugs Rules, 1945 as an authorised port for drug imports. | Expands India’s regulated pharmaceutical import infrastructure. |
Legal framework | The notification has been issued through the Drugs (Ninth Amendment) Rules, 2026 after consultation with the Drugs Technical Advisory Board. | Follows the statutory process prescribed under the Drugs and Cosmetics Act, 1940. |
Import network | The number of authorised ports for importing drugs across air, sea, road and rail increases from 41 to 42. | Provides greater flexibility for routing pharmaceutical consignments. |
Trade logistics | Navi Mumbai Airport becomes an additional regulated gateway for importing medicines and pharmaceutical products. | Can improve supply chain efficiency and reduce logistical bottlenecks as cargo volumes grow. |
Regulatory oversight | Import approvals, inspections and quality requirements remain unchanged under the existing regulatory framework. | Expands infrastructure without diluting regulatory safeguards. |
India Expands Its Regulated Pharmaceutical Import Network
The Ministry of Health and Family Welfare has amended Rule 43A of the Drugs Rules, 1945 to notify Navi Mumbai Airport as an authorised point for importing drugs into India. Issued through the Drugs (Ninth Amendment) Rules, 2026, the notification follows consultation with the Drugs Technical Advisory Board and expands the country’s network of authorised air, sea, rail and road entry points from 41 to 42.
Rather than changing import standards or regulatory requirements, the amendment expands the physical infrastructure through which pharmaceutical imports can legally enter India.
A Logistics Reform Rather Than a Regulatory Reform
Adding Navi Mumbai Airport provides pharmaceutical importers with an additional regulated gateway, improving routing options for imported medicines, active pharmaceutical ingredients and other regulated drug products. As cargo volumes grow, distributing imports across more authorised entry points can reduce logistical bottlenecks, improve turnaround times and strengthen supply chain resilience.
The amendment complements broader investments in logistics infrastructure by ensuring that regulatory permissions evolve alongside expanding transport capacity.
Regulatory Oversight Remains Unchanged
The notification does not alter India’s drug import approval process or quality standards. All imported drugs will continue to remain subject to the provisions of the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, and oversight by the Central Drugs Standard Control Organisation (CDSCO).
The change is therefore administrative in nature, expanding the list of authorised import gateways while preserving the existing regulatory framework governing pharmaceutical imports.
What is Rule 43A of the Drugs Rules, 1945?
Rule 43A specifies the ports, airports, land customs stations and other authorised entry points through which drugs may legally be imported into India under the Drugs and Cosmetics Act, 1940. Only drugs entering through these notified locations can be processed under the prescribed regulatory and inspection framework. The list includes major gateways such as Mumbai Port, Nhava Sheva Port, Chennai Port, Delhi Air Cargo Complex, and now Navi Mumbai Airport.
Policy Relevance
Expands India’s regulated pharmaceutical logistics network, increasing authorised drug import gateways from 41 to 42.
Improves supply chain flexibility by providing importers with an additional airport for routing pharmaceutical consignments.
Demonstrates how regulatory infrastructure can evolve alongside transport infrastructure, ensuring new logistics hubs become operational for regulated trade.
Maintains India’s regulatory safeguards, with all imported drugs continuing to be governed by the Drugs and Cosmetics Act and CDSCO oversight.
Supports the efficiency of India’s pharmaceutical trade ecosystem without altering import approval or quality standards.
Relevant Question for Stakeholders: As India’s pharmaceutical trade and air cargo capacity continue to expand, how should authorised import gateways, customs infrastructure and regulatory inspection systems evolve together to maintain both supply chain efficiency and quality assurance?
Follow the Full Update Here: Government Notifies Navi Mumbai Airport for Drug Imports Under Drugs Rules